References
- Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. [Internet]. 2011;364:1046–1060. cited 2017 Jul 11. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra1011442
- Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2014 [Internet]. Based November. 2016 SEER data submission, posted to SEER web site, April 2017. Bethesda, US-MD; [cited 2018 Feb 19]. Available from: https://seer.cancer.gov/csr/1975_2014/.
- He W, Goodkind D, Kowal P International population reports, P95/16-1. an aging world: 2015. [Internet]. Washington, US-DC: U.S. Government Publishing Office; 2016 [cited 2018 Feb 19]. Available from: https://www.census.gov/content/dam/Census/library/publications/2016/demo/p95-16-1.pdf.
- Hamaker ME, Jonker JM, De Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol. [Internet] 2012;13:e437–e444. cited 2018 Feb 19. Available from: https://www.sciencedirect.com/science/article/pii/S1470204512702590
- Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. [Internet] 2008;111:2516–2520. cited 2017 Sep 5. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-10-116129
- Pozzi S, Marcheselli L, Bari A, et al. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. Br J Haematol. [Internet] 2013;163:40–46. cited 2018 Feb 19.
- Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98:980–987.
- Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125:2068–2074.
- Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. [Internet] 2015;26:1091–1101. cited 2018 Feb 19. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdu540
- Ellis G, Whitehead MA, Robinson D, et al. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ. [Internet] 2011;343:d6553. cited 2018 Feb 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22034146
- Maas HAAM, Janssen-Heijnen MLG, Olde Rikkert MGM, et al. Comprehensive Geriatric assessment and its clinical impact in oncology. Eur J Cancer. [Internet] 2007;43:2161–2169. cited 2018 Feb 20. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0959804907006132
- Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull. [Internet]. 1988;24:609–614. cited 2018 Feb 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3074322
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. [Internet] 1987;40:373–383. cited 2017 Dec 27. Available from: http://www.sciencedirect.com/science/article/pii/0021968187901718
- Engelhardt M, Dold SM, Ihorst G, et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica. [Internet] 2016;101:1110–1119. cited 2018 Jan 12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27479825
- Engelhardt M, Domm A-S, Dold SM, et al. A concise revised myeloma comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017. haematol.2016.162693.
- Facon T, Hulin C, Dimopoulos MA, et al. A frailty scale predicts outcomes of patients with newly diagnosed multiple myeloma who are ineligible for transplant treated with continuous lenalidomide plus low-dose dexamethasone on the first trial. 2015. cited 2018 Jan 15. Abstract #4239 [ASH 2015 57th Meeting]. Available from: https://ash.confex.com/ash/2015/webprogramscheduler/Paper81170.html
- Milani P, Vincent Rajkumar S, Merlini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91:1129–1134.
- Takeoka Y, Sakatoku K, Miura A, et al. Prognostic effect of low subcutaneous adipose tissue on survival outcome in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16:434–441.
- Bonanad S, González B, Cruz-Jentoft A, et al. GAH SCALE PREDICTS TREATMENT TOLERABILITY IN OLDER PATIENTS (>65 YEARS) DIAGNOSED WITH HEMATOLOGICAL MALIGNANCIES. EHA Learn Cent. [Internet] 2017; cited 2018 Jun 13. Abstract #P376 [EHA 2017 22nd Annual Meeting]. Available from: https://learningcenter.ehaweb.org/eha/2017/22nd/181663/javier.de.la.rubia.gah.scale.predicts.treatment.tolerability.in.older.patients.html
- Auner HW, Szydlo R, Hoek J, et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant. [Internet] 2015;50:209–215. cited 2018 Feb 5. Available from: http://www.nature.com/articles/bmt2014255
- Saad A, Mahindra A, Zhang M-J, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014;20:402–408.e1.
- Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. [Internet] 2016;101:1390–1397. cited 2018 Jan 12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27612987
- Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results (vol 122, pg 1376, 2013). Blood. 2014;123:3843.
- Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. [Internet] 2018;32:383–390. cited 2018 Jun 13. Available from: http://www.nature.com/doifinder/10.1038/leu.2017.211
- McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis. J Clin Oncol. 2017;35:3279–3289.
- Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600.
- Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118:4519–4529.
- Mateos M-V, Oriol A, Martínez-López J, et al. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. [Internet] 2016;95:2033–2041. cited 2018 Feb 20. Available from: http://link.springer.com/10.1007/s00277-016-2835-3
- Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. [Internet] 2011;118:1239–1247. cited 2017 Jun 26. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-03-341669
- Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–3977.
- Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. [Internet] 2011;118:1231–1238. cited 2017 May 8. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-02-338665
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. [Internet] 2008;359:906–917. cited 2017 Jun 26. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0801479
- San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. [Internet] 2013;31:448–455. cited 2018 Jan 12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23233713
- Delforge M, Dhawan R, Robinson D, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. [Internet] 2012;89:16–27. cited 2018 Feb 20.
- Mateos M-V, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. [Internet] 2010;11:934–941. cited 2018 Jan 12. Available from: http://www.sciencedirect.com/science/article/pii/S147020451070187X
- Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. [Internet] 2010;28:5101–5109. cited 2017 Jun 26. Available from: http://ascopubs.org/doi/10.1200/JCO.2010.29.8216
- Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. [Internet] 2010;116:4745–4753. cited 2017 May 9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20807892
- Mateos M-V, Bringhen S, Richardson PG, et al. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. [Internet] 2014;993324. cited. 2018 Feb 20. [Epub ahead of print]: http://www.haematologica.org/content/haematol/early/2014/04/23/haematol.2013.099341.full.pdf
- Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. [Internet] 2011;12:431–440. cited 2017 Jul 6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S147020451170081X
- Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. [Internet] 2014;371:906–917. cited 2017 May 8. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1402551
- Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. [Internet] 2017;389:519–527. cited 2018 Jan 15. Available from: http://www.sciencedirect.com/science/article/pii/S014067361631594X
- De Weers M, Tai Y-T, Van Der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. [Internet] 2011;186:1840–1848. cited 2017 Dec 14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21187443
- Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. [Internet] 2017; cited 2018 Jan 12. [Epub Ahead of print] NEJMoa1714678. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1714678
- Ludwig H, Durie BGM, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. [Internet] 2012;119:3003–3015. cited 2017 May 9. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-11-374249
- Ludwig H, Adam Z, Tóthová E, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. [Internet] 2010;95:1548–1554. cited 2017 Nov 27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20418244
- Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. [Internet] 2012;119:7–15. cited 2018 Feb 20. Available from: http://www.bloodjournal.org/content/119/1/7?sso-checked=true
- Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32:634–640. [Internet]. Available from: http://ascopubs.org/doi/10.1200/JCO.2013.52.0023
- Mateos M-V, Oriol A, Martínez-López J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. [Internet] 2012;120:2581–2588. cited 2017 Jul 31. Available from: http://www.bloodjournal.org/content/120/13/2581.short?sso-checked=true
- Jackson G, Davies FE, Pawlyn C, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma xi trial. Blood. [Internet] 2017;130. Abstract#436 [ASH 2017 59th Meeting]. Available from: http://www.bloodjournal.org/content/130/Suppl_1/436
- Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–1769. [Internet]. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1112704
- Larocca A, Palumbo A. How I treat fragile myeloma patients. Blood. [Internet]. 2015;126:2179–2185. cited 2018 Feb 5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26324701
- Niesvizky R, Flinn IW, Rifkin R, et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. [Internet] 2015;33:3921–3929. cited 2018 Jan 12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26056177
- Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. [Internet] 2016;127:1102–1108. cited 2017 Jul 28. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-08-662627
- Zweegman S, Engelhardt M, Larocca A. Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol. [Internet]. 2017;29:315–321. cited 2018 Feb 20. Available from: https://journals.lww.com/co-oncology/Abstract/2017/09000/Elderly_patients_with_multiple_myeloma___towards_a.3.aspx
- Dimopoulos MA, Laubach J, Echeveste Gutierrez MA, et al. Efficacy and safety of long-term ixazomib maintenance therapy in patients (PTS) with newly diagnosed multiple myeloma (NDMM) not undergoing transplant: an integrated analysis of four phase 1/2 studies. Blood. [Internet] 2017;130. cited. 2018 Feb 20. Abstract#902 [ASH 2017 59th Meeting]: http://www.bloodjournal.org/content/130/Suppl_1/902?sso-checked=true
- Hari P, Romanus D, Luptakova K, et al. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol. [Internet] 2017; cited 2018 Feb 20. [Corrected proof ahead of print]. Available from: https://www.sciencedirect.com/science/article/pii/S1879406817301935
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. [Internet] 2015;372:142–152. cited 2017 Jun 26. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1411321
- Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. [Internet] 2017;177:404–413. cited 2018 Jan 12.
- Salvini M, Troia R, Giudice D, et al. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. [Internet] 2018;14:91–99. cited 2018 Feb 20. Available from: https://www.tandfonline.com/doi/full/10.1080/17425255.2018.1417388
- Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. [Internet] 2016;374:1621–1634. cited 2017 Jun 29. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1516282
- Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. [Internet] 2016;17:27–38. cited 2017 Oct 27. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204515004647
- Ludwig H, Dimopoulos MA, Moreau P, et al. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk. Lymphoma [. [Internet] 2017;58:2501–2504. cited 2018 Feb 20. Available from: https://www.tandfonline.com/doi/full/10.1080/10428194.2017.1298755
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. [Internet] 2016;375:754–766. cited 2017 Oct 26. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1606038
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. [Internet] 2016;375:1319–1331. cited 2017 Oct 26. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1607751
- Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for relapsed or refractory multiple myeloma. N Engl J Med. [Internet] 2015;373:621–631. cited 2017 Jul 14. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1505654
- Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. [Internet] 2017;178:896–905. cited 2018 Feb 20.
- San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
- Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. [Internet] 2016;387:1551–1560. cited 2017 Oct 27. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673615011204
- Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. [Internet]. 2008;111:2521–2526. cited 2018 Feb 20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17901246
- Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. [Internet] 1999;341:2061–2067. cited 2018 Feb 20. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199912303412706
- Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. [Internet] 2018;378:518–528. cited 2018 Feb 20. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1714678
- Zweegman S, Levin M-D, Klein SK, et al. Feasibility and efficacy of dose adjusted melphalan - prednisone - bortezomib (mpv) in elderly patients ≥ 75 years of age with newly diagnosed multiple myeloma; the non-randomised phase ii hovon 123 study. Blood [. [Internet] 2016;128. cited. 2018 Feb 20. Abstract#3305 [ASH 2016 58th Meeting]: http://www.bloodjournal.org/content/128/22/3305